Hims & Hers Health, Inc. (NYSE:HIMS) Stock Position Lessened by Foresite Capital Management V LLC

Foresite Capital Management V LLC reduced its stake in shares of Hims & Hers Health, Inc. (NYSE:HIMS - Free Report) by 46.6% during the 4th quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The institutional investor owned 939,860 shares of the company's stock after selling 819,454 shares during the period. Hims & Hers Health accounts for 18.9% of Foresite Capital Management V LLC's investment portfolio, making the stock its 2nd biggest holding. Foresite Capital Management V LLC owned 0.43% of Hims & Hers Health worth $22,726,000 as of its most recent filing with the Securities & Exchange Commission.

Other hedge funds and other institutional investors also recently made changes to their positions in the company. Farallon Capital Management LLC raised its position in shares of Hims & Hers Health by 64,338.5% in the 4th quarter. Farallon Capital Management LLC now owns 8,377,000 shares of the company's stock valued at $202,556,000 after acquiring an additional 8,364,000 shares during the period. FORA Capital LLC grew its stake in shares of Hims & Hers Health by 81.7% in the fourth quarter. FORA Capital LLC now owns 139,139 shares of the company's stock valued at $3,364,000 after buying an additional 62,553 shares in the last quarter. Deutsche Bank AG raised its stake in Hims & Hers Health by 8.1% in the fourth quarter. Deutsche Bank AG now owns 738,745 shares of the company's stock valued at $17,863,000 after buying an additional 55,215 shares during the period. Cetera Investment Advisers boosted its holdings in shares of Hims & Hers Health by 11.1% during the 4th quarter. Cetera Investment Advisers now owns 14,628 shares of the company's stock worth $354,000 after buying an additional 1,466 shares during the period. Finally, BOKF NA acquired a new stake in shares of Hims & Hers Health during the fourth quarter worth $390,000. 63.52% of the stock is owned by hedge funds and other institutional investors.

Hims & Hers Health Stock Up 16.0%

NYSE HIMS traded up $8.81 during mid-day trading on Tuesday, hitting $64.02. The stock had a trading volume of 77,096,148 shares, compared to its average volume of 18,745,738. Hims & Hers Health, Inc. has a 52-week low of $12.07 and a 52-week high of $72.98. The company has a market cap of $14.33 billion, a price-to-earnings ratio of 145.50 and a beta of 1.84. The company has a 50 day simple moving average of $33.25 and a 200 day simple moving average of $32.74.

Hims & Hers Health (NYSE:HIMS - Get Free Report) last issued its earnings results on Monday, May 5th. The company reported $0.20 earnings per share for the quarter, topping the consensus estimate of $0.12 by $0.08. The company had revenue of $586.01 million during the quarter, compared to the consensus estimate of $535.21 million. Hims & Hers Health had a return on equity of 10.97% and a net margin of 8.19%. The company's revenue was up 110.7% compared to the same quarter last year. During the same quarter in the prior year, the business earned $0.05 earnings per share. As a group, equities analysts anticipate that Hims & Hers Health, Inc. will post 0.29 earnings per share for the current fiscal year.

Insider Transactions at Hims & Hers Health

In other Hims & Hers Health news, insider Soleil Boughton sold 4,152 shares of the firm's stock in a transaction that occurred on Tuesday, February 18th. The shares were sold at an average price of $60.69, for a total transaction of $251,984.88. Following the completion of the sale, the insider now directly owns 157,345 shares in the company, valued at $9,549,268.05. This trade represents a 2.57% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the SEC, which is available at this hyperlink. Also, insider Patrick Harrison Carroll sold 23,287 shares of the stock in a transaction dated Tuesday, March 18th. The shares were sold at an average price of $34.31, for a total value of $798,976.97. Following the completion of the transaction, the insider now owns 209,661 shares of the company's stock, valued at $7,193,468.91. This represents a 10.00% decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders sold 631,660 shares of company stock valued at $24,978,043 over the last three months. 13.71% of the stock is owned by corporate insiders.

Analyst Ratings Changes

HIMS has been the subject of several research reports. TD Cowen downgraded Hims & Hers Health from a "buy" rating to a "hold" rating and dropped their target price for the company from $44.00 to $30.00 in a research report on Tuesday, April 29th. Leerink Partners lifted their target price on shares of Hims & Hers Health from $24.00 to $40.00 and gave the stock a "market perform" rating in a research report on Tuesday, February 25th. Bank of America upped their price target on Hims & Hers Health from $22.00 to $26.00 and gave the company an "underperform" rating in a research report on Tuesday, April 29th. Morgan Stanley reduced their price objective on shares of Hims & Hers Health from $60.00 to $40.00 and set an "equal weight" rating for the company in a research note on Tuesday, April 29th. Finally, Canaccord Genuity Group lifted their price target on Hims & Hers Health from $38.00 to $68.00 and gave the company a "buy" rating in a research report on Wednesday, February 19th. Two equities research analysts have rated the stock with a sell rating, eight have given a hold rating and three have given a buy rating to the company. According to MarketBeat, the company currently has an average rating of "Hold" and a consensus price target of $37.67.

About Hims & Hers Health

Hims & Hers Health, Inc operates a telehealth consultation platform. It connects consumers to healthcare professionals, enabling them to access medical care for mental health, sexual health, dermatology and primary care. The company was founded in 2017 and is headquartered in San Francisco, CA.